z-logo
Premium
Primary angiosarcoma of the breast: Observations in Asian Indian women
Author(s) -
Shet Tanuja,
Malaviya Alopa,
Nadkarni Mandar,
Kakade Anagha,
Parmar Vani,
Badwe Rajan,
Chinoy Roshni
Publication year - 2006
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20593
Subject(s) - angiosarcoma , medicine , lumpectomy , mastectomy , immunohistochemistry , radiation therapy , sarcoma , hemangiosarcoma , breast cancer , metastasis , cancer , pathology , radiology
Background Primary angiosarcomas of breast are rare tumors, with a fatal outcome. Material and Methods We studied histological prognostic factors and c‐kit expression by immunohistochemistry (IHC) in 12 angiosarcomas accessioned at a cancer referral center in India. Results All patients had primary angiosarcoma; no case of secondary angiosarcoma was accessioned during the study period. Median age of patients was 24.5 years. Nine patients had intermediate grade tumors, one a well differentiated tumor and three patients had high‐grade tumors. Interesting cases encountered included an epithelioid angiosarcoma and an angiosarcoma arising on the background of a biphasic tumor. Eight patients had lumpectomy, four mastectomy and two patients were given radiotherapy. Of the nine patients (seven type I/II and two high grade) with follow up, eight patients developed disseminated metastases within a year of presentation. The patient with well‐differentiated angiosarcoma also died of metastasis albeit after a longer time. On IHC c‐kit staining was weakly seen in two cases. Conclusion Primary angiosarcoma was fatal in young Indian women even in lower grade tumors. The low expression of c‐kit on IHC suggests that targeting this protein for therapy may not be successful in treating these tumors. J. Surg. Oncol. 2006;94:368–374. © 2006 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here